The S&P 500 closed higher on Monday, ending a five-day losing streak as investors focused on potential corporate tax hikes and upcoming economic data. The Dow Jones Industrial Average also advanced, but the Nasdaq Composite Index ended lower. Investors favored value over growth, with stocks set to benefit most from a resurging economy enjoying the biggest percentage gains.
The S&P 500 closed higher on Monday, ending a five-day losing streak as investors focused on potential corporate tax hikes and upcoming economic data. The Dow Jones Industrial Average also advanced, but the Nasdaq Composite Index ended lower. Investors favored value over growth, with stocks set to benefit most from a resurging economy enjoying the biggest percentage gains.
The following bids, mergers, ** AbbVie (ABBV) and Regenxbio Inc (RGNX) have entered a partnership to develop and commercialize RGX-314, a gene therapy candidate for the treatment of chronic retinal diseases, the pharmaceutical companies said.
The following bids, mergers, acquisitions. ** U.S. payments giant PayPal Holdings Inc (PYPL) said it would acquire Japanese buy now, pay later firm Paidy in a $2.7 billion largely cash deal, taking another step to claim the top spot in an industry experiencing a pandemic-led boom.
U.S. lab products provider Avantor Inc (AVTR) will buy Masterflex from privately held Antylia Scientific in a $2.9 billion all-cash deal to beef up its COVID-19 therapy and vaccine manufacturing operations.
Aditxt Inc (ADTX): * ADITXT (ADTX), INC. SIGNS LETTER OF INTENT FOR EXCLUSIVE RIGHTS TO NEGOTIATE THE ACQUISITION OF A BIOPHARMACEUTICAL COMPANY COMMERCIALIZING AND DISTRIBUTING ANTIVIRAL ORAL THERAPY FOR COVID-19. * Aditxt Inc (ADTX) - KEY TERMS OF PROPOSED DEAL INCLUDE COMPLETION OF A PROPOSED $6.5M SECURED LOAN FROM ADITXT TO TARGET COMPANY BY AUGUST 31, 2021.
BioLife Solutions Inc (BLFS): * BIOLIFE SOLUTIONS TO ACQUIRE SEXTON BIOTECHNOLOGIES TO EXPAND CELL AND GENE THERAPY TOOLS PORTFOLIO. * BIOLIFE - TO ACQUIRE REMAINING SHARES OF SEXTON THAT IT DOES NOT CURRENTLY OWN, FOR $24.0 MILLION, IN CONSIDERATION FOR 506,382 NEWLY ISSUED SHARES. * BioLife Solutions Inc (BLFS) - BIOLIFE WILL RETAIN 19.9% OF CONSIDERATION DUE TO SEXTON SHAREHOLDERS.
Liminal BioSciences Inc (LMNL): * LIMINAL BIOSCIENCES ANNOUNCES SALE OF PRIORITY REVIEW VOUCHER FOR $105 MILLION. * Liminal BioSciences Inc (LMNL) - UNIT PROMETIC BIOTHERAPEUTICS ENTERED INTO A DEFINITIVE AGREEMENT TO SELL ITS RARE PEDIATRIC DISEASE PRIORITY REVIEW VOUCHER. * Liminal BioSciences Inc (LMNL) - PRV WAS GRANTED BY U.S. FDA WITH APPROVAL OF RYPLAZIM Source text for Eikon: Further company coverage:
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
Log In Required
